Kidney cancer (Renal cancer)
Luteon TLX250-302
A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (177Lu-DOTA-girentuximab) with the Investigator’s Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC)
Trial overview
Clinical Area
THA
Disease
Kidney
Disease site
Genitourinary (GU)
Study Phase
III
Trial Identifiers
Registration number: NCT07197580
Principal Investigator(s)
··
··